NovaBridge Biosciences (NBP) Cash from Investing Activities (2019 - 2024)

NovaBridge Biosciences (NBP) posted quarterly Cash from Investing Activities of -$109000.0 for Q4 2024, up 99.87% on a QoQ basis from -$81.7 million in Q3 2024.

NovaBridge Biosciences (NBP) Cash from Investing Activities (2019 - 2024) Analysis & Trends

NovaBridge Biosciences (NBP) has reported Cash from Investing Activities for 3 consecutive years, with -$109000.0 the latest figure, recorded in Q4 2024.

  • Quarterly Cash from Investing Activities changed N/A year-over-year to -$109000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2025 was -$81.8 million (up 28.88% YoY) and the FY2025 annual result came in at $105.0 million, up 177.17% from the prior year.
  • Cash from Investing Activities climbed to -$109000.0 in Q4 2024 per NBP's latest filing, from -$81.7 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for NBP reached as high as $8.2 million in Q4 2020 and fell as low as -$81.7 million in Q3 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn -45.51 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -431.90 Mn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -428.90 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - 172.62 Mn
10 NovaBridge Biosciences 397.57 Mn 397.57 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 -109,000.00
Dec 31, 2024 -109,000.00
Sep 30, 2024 -81.66 Mn
Sep 30, 2024 -81.66 Mn
Dec 31, 2020 8.22 Mn
Dec 31, 2020 8.22 Mn
Sep 30, 2020 -41.43 Mn
Sep 30, 2020 -41.43 Mn
Dec 31, 2019 10.97 Mn
Dec 31, 2019 10.97 Mn